Author(s)

Hakima Abid^1,2, Hajar Cherkaoui^1,2, Maria Lahlali^1,2, Nada Lahmidani^1,2, Sidi Adil Ibrahimi^1,2, Mohammed El Abkari^1,2

¹Department of Hepato-gastroenterology, Hassan II University Hospital, Fez, Morocco.
²Faculty of Medicine and Pharmacy of Fez, University of Sidi Mohammed Ben Abdellah, Fez, Morocco.

SARS-Cov-2 is a novel coronavirus discovered in Wuhan, China in late 2019 and responsible for respiratory distress. Aim: study the impact of COVID-19 among patients with cirrhosis. Patients and methods: We conducted a prospective study for a period of 9 months (April 1st-December 1st) that included cirrhotic patients infected with SARS-Cov-2 followed in the gastroenterology department in the University Hospital Hassan II. Results: Among 1437 patients hospitalised for SARS-Cov-2, 8 cirrhotic patients were included in a period of 9 months (April 1st-December 1st). The mean age is 55 y/o and most are female (n = 6). The aetiology of cirrhosis is mostly HCV (n = 3), HBV (n = 2). Half of the infected patients had acute bleeding (one of them had hepatic encephalopathy) and one patient had respiratory distress. Most of the patients had a negative PCR at the end of the hospital stay (n = 5). The mortality rate was 25% and patients were followed up for a period of 4 months. Conclusion: In the studied population, clinical manifestations were essentially a decompensation of cirrhosis.

SARS-Cov-2, Cirrhosis, Decompensation, Severity

Abid, H. , Cherkaoui, H. , Lahlali, M. , Lahmidani, N. , Ibrahimi, S. and Abkari, M. (2021) What Impact Does COVID-19 Have in Cirrhotics?. Open Journal of Gastroenterology, 11, 16-27. doi: 10.4236/ojgas.2021.111002.